ClinicalTrials.gg
CompletedNCT00331487Updated Feb 28, 2012

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

A Phase 3 interventional study of Pioglitazone and Rosiglitazone in Diabetes Mellitus, sponsored by Takeda. Completed at 67 sites in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2012-02-28.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
719
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
10th of 122
719 · median 103
Started
2000
with 3 others
Phase 3
31 of 122
1 open now
Registered
17th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 4 that started in 2000, is one of 31 in phase 3, and was the 17th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes

Read the detailed description

At least two metabolic defects contribute to the development of type 2 diabetes mellitus: relative insulin insufficiency and insulin resistance. The majority of patients with type 2 diabetes mellitus demonstrate some degree of insulin resistance. Even in the absence of hyperglycemia (high blood sugar), insulin resistance is associated with a cluster of metabolic abnormalities that increase the risk for cardiovascular disease, including dyslipidemia (unhealthy blood fat), increased expression of inflammatory markers, activation of pro-coagulants (pro-clotting), hemodynamic changes, and endothelial dysfunction.

The dyslipidemia associated with insulin resistance and type 2 diabetes mellitus is characterized by elevated triglyceride levels and decreased high-density lipoprotein (good) cholesterol levels. Although low-density lipoprotein (bad) cholesterol levels may not be significantly elevated in patients with type 2 diabetes mellitus, an increase in the proportion of small, dense low-density lipoprotein cholesterol particles of increased atherogenicity (increased formation of lipid deposits in the arteries) is observed. When compared with individuals without type 2 diabetes mellitus, the risk of cardiovascular disease is 2- to 4-fold greater in patients with type 2 diabetes mellitus, and the dyslipidemia of diabetes is an important contributor to the increased risk in this population.

By targeting the insulin resistance underlying type 2 diabetes mellitus, the thiazolidinedione class of oral antihyperglycemic medications possesses both a glucose-lowering effect and the potential to alter lipid/lipoprotein metabolism. Two thiazolidinediones are currently available for the treatment of type 2 diabetes mellitus: pioglitazone hydrochloride (ACTOS, Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL) and rosiglitazone maleate (Avandia, GlaxoSmithKline, Research Triangle Park, NC).

The purpose of this study is to evaluate the triglyceride-lowering effects of pioglitazone to rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia who are not receiving any other glucose- or lipid-lowering therapies at the same time as the study medications.

Individuals who participate in this study will provide written informed consent and will be required to commit to a screening visit and approximately 7 additional visits at the study center. Study participation is anticipated to be about 39 weeks (or approximately 8 months). Multiple procedures will occur at each visit which may include fasting, blood collection, physical examinations and electrocardiograms. Participants will be required to follow a diabetic diet, self-monitor their blood glucose and maintain a study diary for the duration of the study.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus
  • Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 719 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus according to the World Health Organization criteria and have diabetes-associated dyslipidemia (fasting triglycerides level between greater than or equal to 150 mg per dL and less than or equal to 600 mg per dL, and a fasting direct low-density lipoprotein cholesterol less than or equal to 130 mg per dL).
  • Fasting serum C-peptide greater than or equal to1 ng per
  • Glycosylated greater than or equal to 7% and less than or equal to 11% if naive to oral antihyperglycemic medications, or greater than or equal to 9.5% if previously treated with oral antihyperglycemic monotherapy

Exclusion criteria

Exclusion Criteria

  • Investigator site personnel and their immediate families. Immediate family defined as a spouse, parent, child or sibling, whether biological or legally adopted.
  • Treatment with a drug within 30 days of Visit 1 that had not received regulatory approval.
  • Treatment within 60 days of Visit 1 with any of the following:

    • insulin
    • systemic therapy (excluding topical and inhaled preparations)
    • combination glycemic therapy (two or more oral anti-diabetes medications)
    • any lipid-lowering agent (including nicotinic acid, fibrates, bile acid resin binders, statins, d thyroxine or neomycin)
    • any weight loss agent (prescription or over the counter)
  • Pregnant, breast feeding, or intending to become pregnant during the study.
  • Serum creatinine greater than or equal to 176.8 μmol per L or greater than or equal to 2 plus per dipstick.
  • Proteinuria at Visit 1.
  • or aspartate transaminase greater than or equal to 1.5 times the at Visit 1 or had significant clinical signs or symptoms of liver disease.
  • History of signs or symptoms of liver disease, such as jaundice or alanine transaminase greater than or equal to 1.5 times the upper limit of normal, while treated with any thiazolidinedione
  • less than 10.5 g per dL for females and less than11.5 g per dL for males at Visit 1.
  • Clinically or biochemically based on thyroid stimulating hormone at Visit 1 hypothyroid or hyperthyroid.
  • History of myocardial infarction, acute cardiovascular event, or heart surgery within 6 months of Visit 1.
  • Functional Cardiac Class III or IV disease.
  • Receiving renal dialysis or has had received a renal transplant.
  • Undergoing therapy for a other than basal cell or squamous cell skin cancer.
  • Clinical signs or symptoms of drug or alcohol abuse.
  • History of infection.
  • Allergy to any glitazone drug.
  • Medical history or the presence of any or unstable medical condition that made the patient unlikely to complete the study.
  • Any condition or situations that precluded adherence and completion of the protocol or a precluding ability to voluntarily give .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
719 participants (actual)

Study arms

  • Experimental
    Pioglitazone QD

    Drug: Pioglitazone

  • Active comparator
    Rosiglitazone QD

    Drug: Rosiglitazone

Interventions

  • Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks

    Also known as: Actos, AD4833

  • Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks

07

What researchers measure

Primary outcomes

  1. Change in fasting triglyceride level

    Time frame: Final Visit

Secondary outcomes

  1. Change in fasting low-density lipoprotein cholesterol.

    Time frame: Final Visit

  2. Change in fasting high-density lipoprotein cholesterol.

    Time frame: Final Visit

  3. Change in fasting total cholesterol.

    Time frame: Final Visit

  4. Change in fasting free fatty acids.

    Time frame: Final Visit

  5. Change in plasminogen activator inhibitor 1

    Time frame: Final Visit

  6. Change in high-sensitivity C-reactive protein

    Time frame: Final Visit

  7. Change in fasting C-peptide.

    Time frame: Final Visit

  8. Homeostasis model assessment-insulin resistance mode.

    Time frame: Final Visit

  9. Change in fasting insulin.

    Time frame: Final Visit

  10. Homeostasis model assessment-beta cell function.

    Time frame: Final Visit

  11. Change in glycosylated hemoglobin.

    Time frame: Final Visit

  12. Change in fasting plasma glucose.

    Time frame: Final Visit

  13. Low-density lipoprotein particle concentration.

    Time frame: Final Visit

  14. Low-density lipoprotein particle size.

    Time frame: Final Visit

  15. High-density lipoprotein particle size.

    Time frame: Final Visit

  16. Very low-density lipoprotein particle size.

    Time frame: Final Visit

  17. Apolipoprotein A-I.

    Time frame: Final Visit

  18. Apolipoprotein B

    Time frame: Final Visit

  19. Lipoprotein a

    Time frame: Final Visit

  20. Apolipoprotein C-III.

    Time frame: Final Visit

08

Study locations

67 sites
  • Anniston, Alabama 36207, United States
  • Birmingham, Alabama 35234, United States
  • Tucson, Arizona 85710, United States
  • Concord, California 94520, United States
  • Fremont, California 94538, United States
  • Los Angeles, California 90095, United States
  • Palos Verdes Estates, California 90274, United States
  • San Diego, California 92120, United States
  • Santa Barbara, California 93105, United States
  • Santa Rosa, California 95405, United States
  • Aurora, Colorado 80010, United States
  • Englewood, Colorado 80110, United States
  • Avon, Connecticut 06001, United States
  • Hamden, Connecticut 06518, United States
  • Longwood, Florida 32750, United States
  • Miami, Florida 33133, United States
  • Miami, Florida 33136, United States
  • Atlanta, Georgia 30342, United States
  • Fayetteville, Georgia 30214, United States
  • Honolulu, Hawaii 96814, United States
  • Idaho Falls, Idaho 83404, United States
  • Chicago, Illinois 60610, United States
  • Indianapolis, Indiana 46202, United States
  • South Bend, Indiana 46601, United States
  • New Orleans, Louisiana 70127, United States
  • Baltimore, Maryland 21204, United States
  • Frederick, Maryland 21702, United States
  • Salisbury, Massachusetts 01952, United States
  • South Yarmouth, Massachusetts 02664, United States
  • Waltham, Massachusetts 02453, United States
  • Minneapolis, Minnesota 55416, United States
  • Chesterfield, Missouri 63017, United States
  • Omaha, Nebraska, United States
  • East Setauket, New York 11733, United States
  • Endwell, New York 13760, United States
  • New York, New York 10025, United States
  • Rochester, New York 14607, United States
  • Staten Island, New York 10305, United States
  • Charlotte, North Carolina 28211, United States
  • Durham, North Carolina 27713, United States
  • Greenville, North Carolina 27834, United States
  • Morehead City, North Carolina 28557, United States
  • Wilmington, North Carolina 28412, United States
  • Columbus, Ohio 43210, United States
  • Franklin, Ohio 45005, United States
  • Tulsa, Oklahoma 74136, United States
  • Portland, Oregon 97201, United States
  • Salem, Oregon 97302, United States
  • Philadelphia, Pennsylvania 19124, United States
  • Pottstown, Pennsylvania 19464, United States
  • Providence, Rhode Island 02908, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Knoxville, Tennessee 37909, United States
  • Memphis, Tennessee 38119, United States
  • Beaumont, Texas 77701, United States
  • Conroe, Texas 77384, United States
  • Dallas, Texas 75390, United States
  • Houston, Texas 77024, United States
  • Lake Jackson, Texas 77566, United States
  • San Antonio, Texas 78229, United States
  • Ogden, Utah 84403, United States
  • Mechanicsville, Virginia 23111, United States
  • Newport News, Virginia 23606, United States
  • Virginia Beach, Virginia 23455, United States
  • Federal Way, Washington 98003, United States
  • Wenatchee, Washington 98801, United States
  • Milwaukee, Wisconsin 53209, United States
09

References and documents

Publications

  • Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005 Jul;28(7):1547-54. doi: 10.2337/diacare.28.7.1547. PubMed 15983299 ↗
  • Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2007;25(1):39-54. doi: 10.2165/00019053-200725010-00005. Erratum In: Pharmacoeconomics. 2007;25(3):237. PubMed 17192117 ↗
  • Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007 Oct;30(10):2458-64. doi: 10.2337/dc06-1903. Epub 2007 Jun 26. PubMed 17595355 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2006
First posted
May 31, 2006
Start
Sep 2000
Primary completionActual
Mar 2004
CompletionActual
Mar 2004
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00331487
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 31, 2006
Start date
Sep 2000
Primary completion
Mar 2004
Completion
Mar 2004
Last update
Feb 28, 2012

Study contacts

Alfonso Perez, MD
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion